Advances in the management of diabetic kidney disease: beyond sodium-glucose co-transporter 2 inhibitors
Anthony T. P. Chan, Sydney C. W. Tang
Kidney Res Clin Pract. 2022;41(6):682-698.   Published online 2022 Jul 19     DOI: https://doi.org/10.23876/j.krcp.21.285
Citations to this article as recorded by Crossref logo
Obesity-related hypertension and chronic kidney disease: from evaluation to management
Mi-Hyang Jung, Sang-Hyun Ihm
Kidney Research and Clinical Practice.2023; 42(4): 431.     CrossRef
Intrarenal Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors on Tubuloglomerular Feedback and Natriuresis
Eun Sil Koh, Gheun-Ho Kim, Sungjin Chung
Endocrinology and Metabolism.2023; 38(4): 359.     CrossRef
Molecular Mechanistic Pathways Targeted by Natural Compounds in the Prevention and Treatment of Diabetic Kidney Disease
Kaixuan Zhou, Xue Zi, Jiayu Song, Qiulu Zhao, Jia Liu, Huiwei Bao, Lijing Li
Molecules.2022; 27(19): 6221.     CrossRef